Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Social anxiety disorder (SAD) is a common mental health problem that tends to be chronic in nature; fortunately, effective pharmacotherapy options exist. The current study provides an updated meta-analytic review of their efficacy and potential guidelines for their application in SAD. METHODS: A comprehensive search of the current literature yielded 39 randomized, pill placebo-controlled trials of pharmacotherapy for adults diagnosed with SAD. Data on potential moderators of treatment outcome were collected, as well as data necessary to calculate effect sizes using Hedges's g. RESULTS: The overall effect size of pharmacotherapy for SAD is small to medium (Hedges's g = 0.39). The most effective pharmacotherapy type was phenelzine (Hedges's g = 1.14), followed by paroxetine (Hedges's g = 0.49), venlafaxine ER (Hedges's g = 0.45) and moclobemide (Hedges's g = 0.23). CONCLUSION: Effect sizes were not moderated by age, sex, length of treatment, diagnostic subtype initial severity, maximum potential dose, or publication year. It is concluded that pharmacotherapy is effective for treating SAD, but there is considerable variation and room for further improvement. Future directions may include pharmacological enhancement of psychological processes, such as d-cycloserine augmentation of exposure procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561 · cited 3×
“Medication class Medication Study Hedges’s g SE 95% CI low 95% CI high Z p Anticonvulsant Gabapentin Pande et al. (1999) [52] 0.53 0.24 0.05 1.00 2.18 0.03 Pregabalin (150 mg) Pande et al. (2004) [53] -0.09 0.21 -0.50 0.33 -0.42 0.67 Pregabalin (600 mg) Pande et al. (2004) [53] 0.17 0.21 -0.23 0.58 0.84 0.40 Pooled pr…”
InfluentialAugmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 1×
“However, combination strategies showed no benefit over standalone treatment in the long term [21].”
BackgroundSelf-citationCognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 6×
“Phenelzine (Hedges’s g = 1.17) significantly outperformed all of the other three medications, with paroxetine (Hedges’s g = 0.49) and venlafaxine ER (Hedges’s g = 0.45) demonstrating no differences in efficacy, and both outperforming moclobemide (Hedges’s g = 0.23).”
InfluentialFluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415 · cited 3×
“Medication class Medication Study Hedges’s g SE 95% CI low 95% CI high Z p Anticonvulsant Gabapentin Pande et al. (1999) [52] 0.53 0.24 0.05 1.00 2.18 0.03 Pregabalin (150 mg) Pande et al. (2004) [53] -0.09 0.21 -0.50 0.33 -0.42 0.67 Pregabalin (600 mg) Pande et al. (2004) [53] 0.17 0.21 -0.23 0.58 0.84 0.40 Pooled pr…”
InfluentialCognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404 · cited 2×
“Recent studies have demonstrated that CBT, though similar in efficacy to pharmacotherapy with an effect size of 0.62 in a meta-analysis of 5 RCTs [18]), may have longer-lasting effects [19,20].”
BackgroundInfluentialGuastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.011 · Cited by 326 · cited 2×
“Though the DCS evidence base is currently mixed [23], accumulating evidence from several post-hoc analyses indicate that null findings may be due to a lack of focus on the success of the exposure session [25-27].”
BackgroundPande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227 · cited 3×
“…et al. (1999) [52] 0.53 0.24 0.05 1.00 2.18 0.03 Pregabalin (150 mg) Pande et al. (2004) [53] -0.09 0.21 -0.50 0.33 -0.42 0.67 Pregabalin (600 mg) Pande et al. (2004) [53] 0.17 0.21 -0.23 0.58 0.84 0.40 Pooled pregabalin 0.05 0.15 -0.24 0.33 0.30 0.76 Levetiracetam Zhang et al. (2005) [65] 0.39…”
InfluentialBlanco, C., Heimberg, R. G., Schneier, F. R., Fresco, D. M., Chen, H., Turk, C. L., Vermes, D., Erwin, B. A., Schmidt, A. B., Juster, H. R., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.11 · Cited by 206 · cited 3×
“Medication class Medication Study Hedges’s g SE 95% CI low 95% CI high Z p Anticonvulsant Gabapentin Pande et al. (1999) [52] 0.53 0.24 0.05 1.00 2.18 0.03 Pregabalin (150 mg) Pande et al. (2004) [53] -0.09 0.21 -0.50 0.33 -0.42 0.67 Pregabalin (600 mg) Pande et al. (2004) [53] 0.17 0.21 -0.23 0.58 0.84 0.40 Pooled pr…”
Influential
Cited by
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
“13 (NNT = 13.5; Davis et al., 2014) and another reported an SMD of –0.”
BackgroundInfluentialSystematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
“Our meta-analysis confirms previous findings that SSRIs are effective in the treatment of anxiety disorders in adults (Davis et al., 2014; Fedoroff & Taylor, 2001; Hedges et al., 2007; Otto et al., 2001; D. J. Stein et al., 2000).”
ResultPharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Curtiss, J., Andrews, L., Davis, M., Smits, J., & Hofmann, S. G. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285907 · Cited by 46
“relatively little is known about the potential mechanisms underlying pharmacotherapy [7].”
BackgroundResultSelf-citation
Metadata
- Authors
- Davis, M. L., Smits, J. A., & Hofmann, S. G.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2014-10-05
- Volume
- 15
- Issue
- 16
- Pages
- 2281-2291
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2034696987
- Cited by
- 21
- References
- 15
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. https://app.cochat.ai/papers/10.1517/14656566.2014.955472
- The paper
- Davis, M. L., Smits, J. A., & Hofmann, S. G. (2014). Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2014.955472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.